1,4,7-triazacyclononane-n,n',n''-triacetic acid has been researched along with sirolimus in 1 studies
| Studies (1,4,7-triazacyclononane-n,n',n''-triacetic acid) | Trials (1,4,7-triazacyclononane-n,n',n''-triacetic acid) | Recent Studies (post-2010) (1,4,7-triazacyclononane-n,n',n''-triacetic acid) | Studies (sirolimus) | Trials (sirolimus) | Recent Studies (post-2010) (sirolimus) |
|---|---|---|---|---|---|
| 195 | 3 | 161 | 20,711 | 2,368 | 11,516 |
| Protein | Taxonomy | 1,4,7-triazacyclononane-n,n',n''-triacetic acid (IC50) | sirolimus (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 10 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 1.25 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 2 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 2 | |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Mus musculus (house mouse) | 0.001 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 4 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0897 | |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Homo sapiens (human) | 0.0042 | |
| Regulatory-associated protein of mTOR | Homo sapiens (human) | 0.225 | |
| Target of rapamycin complex subunit LST8 | Homo sapiens (human) | 0.225 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 1.9 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 1.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arbeit, JM; Chang, AJ; Lapi, SE; Lu, ZH; Sohn, R | 1 |
1 other study(ies) available for 1,4,7-triazacyclononane-n,n',n''-triacetic acid and sirolimus
| Article | Year |
|---|---|
Detection of rapalog-mediated therapeutic response in renal cancer xenografts using ⁶⁴Cu-bevacizumab immunoPET.
Topics: Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Cell Line, Tumor; Cell Transformation, Neoplastic; Copper Radioisotopes; Everolimus; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Kidney Neoplasms; Mice; Neovascularization, Pathologic; Phosphorylation; Positron-Emission Tomography; Sirolimus; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |